Cytovance Biologics

Oklahoma City, OK
Microbial Fermentation Biologics Recombinant Proteins Mammalian Cell Culture Plasmid DNA
Program data pending ClinicalTrials.gov matching · Last scored 2026-04-29
61.5
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (8) ○ EMA GMP ○ MHRA GMP

Quick Facts: Cytovance Biologics

Signal Score
61.5/100 (as of 2026-04-29)
Quality Compliance
Assessment pending
Headquarters
Oklahoma City, OK
Founded
2006
Max Bioreactor Scale
2,000L
Website
Modalities
Microbial Fermentation, Biologics, Recombinant Proteins, Mammalian Cell Culture, Plasmid DNA
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesMicrobial Fermentation, Biologics, Recombinant Proteins, Mammalian Cell Culture, Plasmid DNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 63.0
Broad modality coverage (5 modalities)
Sites: Oklahoma City, OK
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
StatusAvailable
Broad modality coverage (5 modalities)
Sites: Oklahoma City, OK
Recent Press8 articles
Broad modality coverage (5 modalities)

Recent News 8 articles

general 2026-04-02
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - BioSpace
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing  BioSpace
Source →
general 2026-04-02
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - Sahm
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing  Sahm
Source →
general 2026-04-01
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 with Selection of Cytovance Biologics for cGMP Manufacturing - irw-press.com
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 with Selection of Cytovance Biologics for cGMP Manufacturing  irw-press.com
Source →
general 2026-04-01
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - StreetInsider
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing  StreetInsider
Source →
general 2026-04-01
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - Yahoo Finance Singapore
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing  Yahoo Finance Singapore
Source →
general 2026-04-01
Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Trials with Cytovance Biologics as cGMP Manufacturer - geneonline.com
Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Trials with Cytovance Biologics as cGMP Manufacturer  geneonline.com
Source →
general 2026-04-01
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - PR Newswire
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing  PR Newswire
Source →
general 2026-04-01
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - Morningstar
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing  Morningstar
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Microbial Fermentation CDMOs → Biologics CDMOs → Recombinant Proteins CDMOs → Mammalian Cell Culture CDMOs → Plasmid DNA CDMOs →

Similar CDMOs

Richter BioLogics
Hamburg, DE
Signal Score: 82.9
Plasmid DNA, Recombinant Proteins, VHH/Nanobodies, Bacterial Vaccines, Biologics
3P Biopharmaceuticals (now 3PBIOVIAN)
Pamplona-Noáin, Spain
Biologics (microbial & mammalian), AAV, Adenoviral, Lentiviral, Cell Therapy, Plasmid DNA, Recombinant Proteins, Biosimilars, Fill/Finish (recombinant proteins & viral vectors)
BioCina
Adelaide, Australia
Biologics (Microbial), Plasmid DNA, mRNA, LNP, Sterile Fill-Finish, Recombinant Proteins, Vaccines, Biosimilars, High Potency/Oncology Injectables, Blow-Fill-Seal
Altruist Biologics
Suzhou, China
Biologics, mAb, Bispecific/Multispecific Antibodies, Fusion Proteins, Recombinant Proteins, ADC, Cell Therapy, Gene Therapy
Olon Group
Rodano (Milan), Italy
Small Molecule API, HPAPI / Cytotoxics, Microbial Fermentation, Mammalian Cell Culture, Recombinant Proteins / Enzymes, Biologics (mAbs), ADC (end-to-end bioconjugation), Oligonucleotide / Peptide, Chemical Synthesis, Semi-Synthesis